共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肺癌耐药的新机制——肺癌的病理转化显示文摘研究人员在提高肺癌疗效方面做出了很大努力,但其预后仍不令人满意。主要原因是对耐药机制缺乏全面的了解,缺少有效的临床治疗方法的研究。根据肺癌研究的最新进展,我们将耐药机制分为分子、细胞和病理3个水平,这3个层面对临床耐药性的获得和演变都具有重要的意义。对耐药机制的研究已经开始改变临床治疗方法,改善了患者预后。在本综述中,我们重点讨论了在过去的几十年中被忽视了的与耐药相关的病理改变。 | 陈玥清 Waiying Yvonne Tang 童欣媛 季红斌 | 2020 | 癌症2020，39，9： | 1 |
| 2 | Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer显示文摘Dear Editor,Gastric cancer(GC)is a leading cause of cancer-related deaths worldwide,especially in China and other East Asian countries[1,2].Although considerable achievements have been made in its treatment[3]and predictive biomarkers[4]in past decades,the prognosis of GC remains poor[5].Therefore,more effective prognostic markers are needed to improve the prognosis prediction of GCs.Small panels based on next-generation sequencing,such as FoundationOne CDx and MSK-IMPACT,are widely used for selecting appropriate treatment approaches(such as targeted therapies,immunotherapies,and chemotherapies)with the advantages of a higher sequencing depth and more cost-effectiveness than whole-exome sequencing(WES).Previous studies have demonstrated that molecular characteristics based on the designed cancer-related gene panel were consistent with those determined by WES and could be prognostic markers for various cancer types[6-8].As such,we analyzed the molecular features with the designed panel to investigate probable prognostic biomarkers for Chinese patients with GC. | Lisheng Cai Linhai Li Dandan Ren Xue Song Beibei Mao Bo Han Henghui Zhang | 2020 | Cancer Communications2020，40，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员